Methods for measuring, enhancing, and accounting for medication adherence in clinical trials

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 617-626

  Vrijens, B ^a   Urquhart, J ^a  

^a MWV Healthcare ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEW DRUG;

ARTICLE; BIOSENSOR; CLINICAL TRIAL (TOPIC); COST; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUSTRY; DRUG MECHANISM; DRUG MONITORING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL DOCUMENTATION; MEDICAL PHOTOGRAPHY; MEDICATION COMPLIANCE; PATENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTOCOL COMPLIANCE; SIGNAL DETECTION; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DOCUMENTATION; DRUG DESIGN; DRUG MONITORING; ELECTRONICS; HUMANS; MEDICATION ADHERENCE; PATIENT COMPLIANCE; PHARMACOKINETICS;

EID: 84901195286     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.59     Document Type: Article

References (71)

1. Vrijens, B. et al.; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 73, 691-705 (2012
2. Harter, J.G. & Peck, C.C. Chronobiology. Suggestions for integrating it into drug development. Ann. N. Y. Acad. Sci. 618, 563-571 (1991
3. Feinstein, A.R. Intent-To-Treat policy for analyzing randomized trials statistical distortions and neglected clinical challenges. In Compliance in Medical Practice and Clinical Trials (eds. Cramer, J.A. & Spilker, B.) 359-370 (Raven press, New York, 1991
4. Blaschke, T.F., Osterberg, L., Vrijens, B. & Urquhart, J. Adherence to medications: Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275-301 (2012
5. Czobor, P. & Skolnick, P. The secrets of a successful clinical trial: Compliance, compliance, and compliance. Mol. Interv. 11, 107-110 (2011
6. Vrijens, B., Vincze, G., Kristanto, P., Urquhart, J. & Burnier, M. Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. BMJ 336, 1114-1117 (2008
7. Sheiner, L.B. & Rubin, D.B. Intention-To-Treat analysis and the goals of clinical trials. Clin. Pharmacol. Ther. 57, 6-15 (1995
8. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. & Peck, C. Postmarketing drug dosage changes of 499 FDA-Approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11, 439-446 (2002
9. Heerdink, E.R., Urquhart, J. & Leufkens, H.G. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf. 11, 447-453 (2002
10. US Food and Drug Administration. Guidance for industry. Enrichment strategies for clinical trials to support approval of human drugs and biological products. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf. Accessed 23 December 2013
11. Kaitin, K.I. The landscape for pharmaceutical innovation: Drivers of costeffective clinical research. Pharm. Outsourcing 11, 28, 30, 32 (2010
12. Paul, S.M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010
13. Miller, G. Is pharma running out of brainy ideas? Science 329, 502-504 (2010
14. Kaitin, K.I. & DiMasi, J.A. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89, 183-188 (2011
15. Kaitin, K.I. Obstacles and opportunities in new drug development. Clin. Pharmacol. Ther. 83, 210-212 (2008
16. Kaitin, K.I. Deconstructing the drug development process: The new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010
17. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009
18. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010
19. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004
20. Lalonde, R. Keynote speech. 2nd PaSiPhIC conference, San Luis Obispo, CA, 13-15 July 2011
21. Djulbegovic, B., Hozo, I. & Ioannidis, J.P. Improving the drug development process: More not less randomized trials. JAMA 311, 355-356 (2014
22. Sacks, L.V., Shamsuddin, H.H., Yasinkaya, Y.I., Bouri, K., Lanthier, M.L., Sherman, R.E. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 311, 378-384 (2014
23. Personalized Medicine Coalition. Personalized medicine: An introduction. http://www.personalizedmedicinecoalition.org/sites/default/files/ personalmed-backgrounder.pdf. Accessed 3 January 2014
24. Centers for Disease Control and Prevention. Office-related antibiotic prescribing for persons aged ≤14 years-United States, 1993-1994 to 2007-2008. Morb. Mortal. Wkly. Rep. 60, 1153-1156 (2011
25. Pullar, T., Kumar, S., Tindall, H. & Feely, M. Time to stop counting the tablets? Clin. Pharmacol. Ther. 46, 163-168 (1989
26. Rudd, P. et al. The natural history of medication compliance in a drug trial: Limitations of pill counts. Clin. Pharmacol. Ther. 46, 169-176 (1989
27. Matsui, D., Hermann, C., Klein, J., Berkovitch, M., Olivieri, N. & Koren, G. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J. Clin. Pharmacol. 34, 944-949 (1994
28. Arnsten, J.H. et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33, 1417-1423 (2001
29. Stone, A.A., Shiffman, S., Schwartz, J.E., Broderick, J.E. & Hufford, M.R. Patient non-compliance with paper diaries. BMJ 324, 1193-1194 (2002
30. Carroll, C.L., Feldman, S.R., Camacho, F.T., Manuel, J.C. & Balkrishnan, R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J. Am. Acad. Dermatol. 51, 212-216 (2004
31. Garber, M.C., Nau, D.P., Erickson, S.R., Aikens, J.E. & Lawrence, J.B. The concordance of self-report with other measures of medication adherence: A summary of the literature. Med. Care 42, 649-652 (2004
32. Vrijens, B., Gross, R. & Urquhart, J. The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/ pharmacodynamic analyses. Basic Clin. Pharmacol. Toxicol. 96, 225-227 (2005
33. Halpern, M.T. et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 47, 1039-1048 (2006
34. Farmer, K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin. Ther. 21, 1074-1090 (1999
35. Vrijens, B., Tousset, E., Rode, R., Bertz, R., Mayer, S. & Urquhart, J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-Time data used as input to individually parameterized pharmacokinetic models. J. Clin. Pharmacol. 45, 461-467 (2005
36. Belknap, R. et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One 8, e53373 (2013
37. Eisenberger, U. et al. Medication adherence assessment: High accuracy of the new Ingestible Sensor System in kidney transplants. Transplantation 96, 245-250 (2013
38. Liu, H. et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Intern. Med. 134, 968-977 (2001
39. Averbuch, M., Weintraub, M. & Pollack, D.J. Compliance assessment in clinical trials: The MEMS device. J. Clin. Res. Pharmacoepidemiol. 4, 199-204 (1990
40. Rubio, A., Cox, C. & Weintraub, M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin. Pharmacokinet. 22, 238-246 (1992
41. Girard, P., Sheiner, L.B., Kastrissios, H. & Blaschke, T.F. Do we need full compliance data for population pharmacokinetic analysis? J. Pharmacokinet. Biopharm. 24, 265-282 (1996
42. Vrijens, B. & Goetghebeur, E. The impact of compliance in pharmacokinetic studies. Stat. Methods Med. Res. 8, 247-262 (1999
43. Savic, R.M. et al.; ANRS 134-COPHAR 3 Study Group. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin. Pharmacol. Ther. 92, 575-583 (2012
44. Burnier, M., Schneider, M.P., Chioléro, A., Stubi, C.L. & Brunner, H.R. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J. Hypertens. 19, 335-341 (2001
45. Marin, D. et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28, 2381-2388 (2010
46. Rosen, M.I., Rigsby, M.O., Salahi, J.T., Ryan, C.E. & Cramer, J.A. Electronic monitoring and counseling to improve medication adherence. Behav. Res. Ther. 42, 409-422 (2004
47. Cramer, J.A. & Rosenheck, R. Enhancing medication compliance for people with serious mental illness. J. Nerv. Ment. Dis. 187, 53-55 (1999
48. Demonceau, J. et al.; ABC Project Team. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: A systematic literature review and meta-Analysis. Drugs 73, 545-562 (2013
49. Sommer, A. & Zeger, S.L. On estimating efficacy from clinical trials. Stat. Med. 10, 45-52 (1991
50. Efron, B. & Feldman, D. Compliance as an explanatory variable in clinical trials. J. Amer. Statist. Assoc. 86, 9-17 (1991
51. Kruse, W. & Weber, E. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur. J. Clin. Pharmacol. 38, 561-565 (1990
52. Urquhart, J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin. Pharmacokinet. 27, 202-215 (1994
53. Urquhart, J. Pharmacodynamics of variable patient compliance: Implications for pharmaceutical value. Adv. Drug Deliv. Rev. 33, 207-219 (1998
54. Paterson, D.L. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21-30 (2000
55. Bangsberg, D.R. et al. Non-Adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181-1183 (2001
56. Lowy, A. et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: Role of duration of drug action. Int. J. Clin. Pract. 65, 41-53 (2011
57. Vrijens, B. & Goetghebeur, E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/ pharmacodynamic population studies. Stat. Med. 23, 531-544 (2004
58. Comté L., Vansteelandt, S., Tousset, E., Baxter, G. & Vrijens, B. Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen. Clin. Trials 6, 403-415 (2009
59. Fischer, K., Goetghebeur, E., Vrijens, B. & White, I.R. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. Biostatistics 12, 247-257 (2011
60. Vrijens, B., Goetghebeur, E., de Klerk, E., Rode, R., Mayer, S. & Urquhart, J. Modelling the association between adherence and viral load in HIV-infected patients. Stat. Med. 24, 2719-2731 (2005
61. Osterberg, L.G., Urquhart, J. & Blaschke, T.F. Understanding forgiveness: Minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 88, 457-459 (2010
62. Comté L., Vrijens, B., Tousset, E., Gérard, P. & Urquhart, J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 34, 549-558 (2007
63. US Food and Drug Administration. Suvorexant safety and efficacy. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM354215. pdf. Accessed 3 January 2014
64. Van Damme, L. et al.; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012
65. Baeten, J. & Celum, C. Oral antiretroviral chemoprophylaxis: Current status. Curr. Opin. HIV AIDS 7, 514-519 (2012
66. Karim, Q.A. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010
67. Grant, R.M. et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010
68. Thigpen, M.C. et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423-434 (2012
69. Baeten, J.M. et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399-410 (2012
70. Haberer, J.E. et al. Adherence to antiretroviral prophylaxis for HIV prevention: A substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 10, e1001511 (2013
71. Karim, S.S. & Karim, Q.A. Antiretroviral prophylaxis: A defining moment in HIV control. Lancet 378, e23-e25 (2011